{
  "event": {
    "ticker": "INO",
    "company": "INOVIO Pharmaceuticals, Inc.",
    "drug": "INO-3107 (DNA plasmid immunotherapy targeting HPV-6/11, given with the CELLECTRA 5PSP electroporation device; no brand name or INN disclosed)",
    "application_type": "BLA",
    "indication": "Adults with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and/or HPV-11; filed under the accelerated approval program",
    "pdufa_date": "2026-10-30"
  },
  "display": {
    "company": "Inovio",
    "drug": "INO-3107",
    "indication_en": "Recurrent respiratory papillomatosis",
    "indication_zh": "复发性呼吸道乳头状瘤病"
  },
  "probability_approval": 0.4,
  "confidence": "low",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "In the filing letter the FDA said accelerated-approval eligibility had not been justified, and it has not withdrawn that view",
      "direction": "-",
      "step": "large",
      "evidence": "In the December 2025 file-acceptance letter, the FDA noted as a potential review issue its preliminary conclusion that INOVIO had not provided adequate information to justify eligibility for the accelerated approval pathway. It also turned down priority review despite Breakthrough designation. At the July 2026 informal meeting the FDA did not discuss that comment, and it declined to comment on eligibility while the file is under review. INOVIO says it is not planning to seek traditional approval, which could require a Phase 3 trial. If the FDA keeps its preliminary view, a CRL is the most likely result.",
      "source": "SEC 10-K filed 2026-03-12; 10-Q filed 2026-05-13; 8-K and 10-Q filed 2026-08-12"
    },
    {
      "factor": "A fully approved competitor raises the bar to 'meaningful advantage over available therapy', and the single-arm data are numerically weaker",
      "direction": "-",
      "step": "medium",
      "evidence": "Precigen's PAPZIMEOS received full approval for adult RRP in August 2025, with a 51% (18/35) complete response at 12 months. That makes it 'available therapy', and accelerated approval now needs a meaningful advantage over it. INO-3107's evidence is one single-arm Phase 1/2 trial (n=32) that compares each patient with their own prior year. Year-1 complete response (no surgery) was 28% (9/32); 81% had fewer surgeries. Year 2, from the retrospective follow-up RRP-002, was 50% (14/28). INOVIO argues the trials are not comparable: it counted every surgery from day 0, whereas 83% of PAPZIMEOS patients had debulking surgeries during dosing. It also argues neutralizing antibodies do not affect its DNA vector. Whether the FDA accepts these arguments is the central uncertainty.",
      "source": "CGTLive / Precigen PAPZIMEOS approval coverage; The Laryngoscope 2025 (PMC12645365); INOVIO remarks at H.C. Wainwright conference, 2026-09-11"
    },
    {
      "factor": "Otherwise the review is proceeding toward an action: mid-cycle and late-cycle meetings are done, inspections are complete, and labeling and confirmatory-trial feedback are expected",
      "direction": "+",
      "step": "medium",
      "evidence": "The mid-cycle meeting (April 2026) raised no new significant issues. The late-cycle meeting is complete. All pre-licence inspections (clinical, manufacturing, device) are done, with a single reported observation that INOVIO says it has addressed. The FDA said its feedback on the confirmatory-trial design is forthcoming. INOVIO expected label negotiations to start in September 2026. As of 2026-10-04 we found no public confirmation that they began. The FDA working on confirmatory-trial design is a modestly positive sign for an accelerated-approval decision.",
      "source": "SEC 8-K 2026-08-12; Q2 2026 earnings call 2026-08-12; H.C. Wainwright conference 2026-09-11"
    },
    {
      "factor": "Precedent in the same disease: CBER gave PAPZIMEOS full approval on a small single-arm trial",
      "direction": "+",
      "step": "small",
      "evidence": "CBER has accepted surgery-free complete response from a roughly 35-patient single-arm trial as substantial evidence in RRP. So in principle the FDA could approve INO-3107 even with no randomized data. New CBER and OTP leadership since mid-2026 (Prasad left in April, the acting OTP director in June) granted INOVIO's informal meeting. Which way the new leadership leans is unknown.",
      "source": "CGTLive PAPZIMEOS approval; STAT 2026-03-06 and 2026-06-29"
    },
    {
      "factor": "First commercial product of a small company: a drug-device combination with a prior device-manufacturing problem",
      "direction": "-",
      "step": "small",
      "evidence": "INO-3107 combines a plasmid with the CELLECTRA 5PSP device. Plasmid supply comes from contract manufacturers; INOVIO's partners include Richter BioLogics and Kaneka Eurogentec. In 2024 a manufacturing defect in the device's single-use array delayed the BLA by about a year. Inspections are now complete with one observation, which limits this risk. INOVIO's cash runway runs only into Q1 2027, with going-concern language, so a CMC CRL would be hard for it to absorb.",
      "source": "SEC 10-Q filed 2026-08-12 (going concern; CDMO supply agreements); INOVIO Q2 2024 results release (device array issue)"
    }
  ],
  "manufacturing_risk": {
    "level": "medium",
    "why": "This is the company's first commercial product: a plasmid DNA medicine made at contract manufacturers and delivered by a proprietary electroporation device, which had an array-manufacturing defect in 2024. All pre-licence inspections are complete with one reported observation, so CMC is secondary to the question of accelerated-approval eligibility."
  },
  "what_would_change_my_mind": [
    "INOVIO confirming that label negotiations or post-marketing requirement and confirmatory-trial discussions with the FDA are under way (up)",
    "Any statement that the FDA has resolved, or reiterated, its preliminary view on accelerated-approval eligibility",
    "A PDUFA extension after a major amendment, for example new comparative analyses against PAPZIMEOS (date change only, mildly informative)",
    "A Form 483 response problem, or a device or CMC information request disclosed late in the review (down)"
  ],
  "summary_en": "We put approval of INOVIO's INO-3107 for recurrent respiratory papillomatosis at 40%, well below the ~76% base rate for small-company original applications. The main factor: in its filing letter the FDA said INOVIO had not justified eligibility for accelerated approval, and it has not publicly reversed that view. Since Precigen's PAPZIMEOS won full approval in 2025, INO-3107 must show a meaningful advantage over it. INO-3107's evidence is a 32-patient single-arm trial with a 28% year-1 complete response, against 51% for PAPZIMEOS. In its favour, the review is on track: late-cycle meeting and inspections are done, and labeling and confirmatory-trial feedback are expected. Confidence is low.",
  "summary_zh": "我们估计 INOVIO 的 INO-3107（复发性呼吸道乳头状瘤病）获批概率为 40%，远低于中小型公司新药约 76% 的基准。最关键的是：FDA 在受理函中初步认为公司未能证明符合加速审批资格，至今未公开改变这一看法。Precigen 的 PAPZIMEOS 已于 2025 年获完全批准，INO-3107 因此必须证明相对现有疗法有实质优势。INO-3107 的证据仅为一项 32 例单臂试验，第一年完全缓解率 28%，PAPZIMEOS 为 51%。有利因素是审评仍按计划推进：后期审评会议和现场检查已完成，公司预计将开展说明书谈判并获得确证性试验反馈。把握度低。",
  "sources": [
    "SEC 10-K, INOVIO, filed 2026-03-12 (file-acceptance letter review issue on accelerated-approval eligibility; priority review denied; PDUFA 2026-10-30)",
    "SEC 10-Q, INOVIO, filed 2026-05-13 (mid-cycle review completed; assessment aid; informal meeting agreed)",
    "https://www.sec.gov/Archives/edgar/data/1055726/000105572626000023/ino-20260630.htm (10-Q filed 2026-08-12: risk factors, no plan to seek traditional approval, going concern, CDMO supply agreements, PAPZIMEOS competition)",
    "SEC 8-K, INOVIO, filed 2026-08-12 (Q2 2026 results: late-cycle meeting and all pre-licence inspections complete; FDA did not discuss eligibility comment; confirmatory-trial feedback forthcoming)",
    "https://www.sec.gov/Archives/edgar/data/1055726/000119312526326785/d253972d8k.htm (8-K 2026-07-31: underwritten offering, ~$18.3M net proceeds)",
    "https://www.fool.com/earnings/call-transcripts/2026/08/12/inovio-ino-q2-2026-earnings-call-transcript/",
    "https://finance.yahoo.com/healthcare/articles/inovio-pharmaceuticals-inc-q2-2026-012145651.html (one inspection observation; CBER/OTP leadership change)",
    "https://www.investing.com/news/transcripts/inovio-at-hc-wainwright-conference-fda-review-and-launch-loom-93CH-4897818 (2026-09-11; label negotiations anticipated September; MRD-surgery comparison)",
    "https://www.cgtlive.com/view/fda-approves-precigen-recurrent-respiratory-papillomatosis-gene-therapy-papzimeos (PAPZIMEOS full approval, 51% CR)",
    "https://pmc.ncbi.nlm.nih.gov/articles/PMC12645365/ (Laryngoscope 2025: INO-3107 year-1 CR 28%, year-2 CR 50%)",
    "https://www.statnews.com/2026/03/06/fda-vinay-prasad-controversial-cber-director-leaving/",
    "https://www.statnews.com/2026/06/29/vijay-kumar-exits-fda-office-of-therapeutic-products/",
    "https://www.prnewswire.com/news-releases/inovio-reports-second-quarter-2024-financial-results-and-recent-business-highlights-302218314.html (2024 CELLECTRA array manufacturing issue)"
  ],
  "zh": {
    "indication": "由 HPV-6 和/或 HPV-11 引起的成人复发性呼吸道乳头状瘤病（RRP）；按加速批准路径申报",
    "key_factors": [
      {
        "factor": "FDA 在受理函中表示加速批准资格依据不足，且至今未撤回这一意见",
        "evidence": "在 2025 年 12 月的受理函中，FDA 将其初步结论列为潜在审评问题：INOVIO 未提供充分信息证明其符合加速批准路径的资格。尽管该产品拥有突破性疗法认定，FDA 仍拒绝给予优先审评。在 2026 年 7 月的非正式会议上，FDA 未讨论这一意见，并表示在审评期间不对资格问题置评。INOVIO 表示不打算寻求常规批准（常规批准可能需要开展 3 期试验）。如果 FDA 维持其初步意见，最可能的结果是完全回应函（CRL）。"
      },
      {
        "factor": "已有获得完全批准的竞品，门槛提高至“较现有疗法具有有意义的优势”，而本品的单臂数据在数值上更弱",
        "evidence": "Precigen 的 PAPZIMEOS 于 2025 年 8 月获得成人 RRP 的完全批准，12 个月完全缓解率为 51%（18/35）。这使其成为“现有疗法”，加速批准现在需要证明相对它具有有意义的优势。INO-3107 的证据来自一项单臂 1/2 期试验（n=32），以每位患者自身前一年的情况作为对照。第 1 年完全缓解（无需手术）率为 28%（9/32）；81% 的患者手术次数减少。来自回顾性随访研究 RRP-002 的第 2 年完全缓解率为 50%（14/28）。INOVIO 认为两项试验不可比：它从第 0 天起计入所有手术，而 83% 的 PAPZIMEOS 患者在给药期间接受了减瘤手术。INOVIO 还认为中和抗体不会影响其 DNA 载体。FDA 是否接受这些论点是核心不确定性。"
      },
      {
        "factor": "除此之外，审评正朝着作出决定的方向推进：中期和后期审评会议已完成，各项检查已结束，预计将收到说明书和确证性试验方面的反馈",
        "evidence": "中期审评会议（2026 年 4 月）未提出新的重大问题。后期审评会议已完成。所有批准前检查（临床、生产、器械）均已完成，仅报告一项观察项，INOVIO 称已完成整改。FDA 表示将就确证性试验设计提供反馈。INOVIO 预计说明书谈判将于 2026 年 9 月启动。截至 2026 年 10 月 4 日，我们未找到谈判已经开始的公开确认。FDA 着手讨论确证性试验设计，对加速批准决定而言是一个温和的积极信号。"
      },
      {
        "factor": "同一疾病中的先例：CBER 基于一项小型单臂试验给予 PAPZIMEOS 完全批准",
        "evidence": "CBER 已在 RRP 中接受一项约 35 例患者的单臂试验中的无手术完全缓解作为实质性证据。因此原则上，即使没有随机数据，FDA 也可能批准 INO-3107。自 2026 年年中以来，CBER 和 OTP 领导层更迭（Prasad 于 4 月离任，OTP 代理主任于 6 月离任），新领导层同意了 INOVIO 的非正式会议请求。新领导层的倾向尚不明确。"
      },
      {
        "factor": "小型公司的首个商业化产品：一款曾出现器械生产问题的药械组合产品",
        "evidence": "INO-3107 由质粒与 CELLECTRA 5PSP 器械组合而成。质粒由合同生产商（CDMO）供应，INOVIO 的合作方包括 Richter BioLogics 和 Kaneka Eurogentec。2024 年，该器械一次性电极阵列的生产缺陷导致生物制品许可申请（BLA）推迟约一年。目前检查已完成，仅有一项观察项，这在一定程度上限制了该风险。INOVIO 的现金仅能支撑至 2027 年第一季度，且披露中含有持续经营能力存疑的表述，因此若收到与化学、生产与控制（CMC）相关的 CRL，公司将难以承受。"
      }
    ],
    "manufacturing_risk_why": "这是公司的首个商业化产品：一款由合同生产商生产的质粒 DNA 药物，通过专有电穿孔器械给药，该器械在 2024 年曾出现电极阵列生产缺陷。所有批准前检查均已完成，仅报告一项观察项，因此相较于加速批准资格问题，CMC 属于次要因素。",
    "what_would_change_my_mind": [
      "INOVIO 确认已与 FDA 展开说明书谈判，或已开始讨论上市后要求及确证性试验（概率上调）",
      "任何表明 FDA 已消除或重申其加速批准资格初步意见的表态",
      "因重大修改导致 PDUFA 目标日期延期，例如提交了与 PAPZIMEOS 的新比较分析（仅改变日期，略有参考意义）",
      "483 表回复出现问题，或在审评后期披露器械或 CMC 方面的信息请求（概率下调）"
    ]
  },
  "recorded_at": "2026-10-04T19:58:02+00:00"
}